The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Transforming growth factor beta: the good, the bad, and the ugly.
Open accessAbstract
A is often the case with peptide growth factors and cytokines, the original activity discovered and identified as TGF-3 merely represented the tip of the iceberg. Not only does it regulate growth, as evident by its name, but TGF-B mediates far-ranging biologic processes including inflammation and host defense, in addition to development, tissue repair, and tumorigenesis. Released locally from platelet stores early in an inflammatory response, TGF-3 is then generated by inflammatory cells themselves as part of the cytokine network. Initially, in its defensive role, TGF-~ mediates the egress of undifferentiated leukocytes and, subsequently, it facilitates resolution of inflammation and promotes tissue repair (1, 2). But this carefully choreographed series of events, which represents the "good" side of TGF-3, is dependent upon a critical balance of the growth factor. It is becoming increasingly evident that too much of a good thing can be bad; excess TGF-B within a lesion has been associated with unresolved inflammation and fibrotic events (1-3). Now, it appears, based on the study by Lowrance et al. (4) in the MRL/Ipr autoimmune murine model, that TGF-3 has an even uglier side, in that its accumulation in the circulation may predispose the host to serious and recurrent infections. Moreover, in humans, genetic and acquired diseases such as systemic lupus erythematosis (SLE) may mirror the MRL/lpr mouse. Under the best of circumstances, TGF-3 provides a link between each of the processes by which cells and/or tissues respond to infection or injury and initiate repair. By increasing adhesion molecules, generating a potent chemotactic gradient, and inducing itself and an array of other factors as part of the cytokine network (5-7), TGF-~ orchestrates leukocyte recruitment and activation. TGF-13 then downregulates these processes by inhibiting the functions of inflammatory cells once they are activated (2, 8) and facilitates healing by promoting fibroblast recruitment and matrix synthesis (3). As recently reviewed (2), this apparent contradictory influence of TGF-3 on cells of the immune system, both stimulatory and inhibitory, is accounted for, in part by the differential effects of TGF-3 on resting and activated cells. As a general, but by no means exclusive rule, resting, immature ceils are stimulated by TGF-3, whereas activated representatives of the same cell populations may be inhibited by TGF-3. Thus, TGF-3 serves as a conversion factor, converting an active inflammatory site into one dominated by resolution and repair. Upsetting the delicate balance of TGF-3 that dictates these events may have pathologic consequences. Indeed, persistent stimulation of immune/inflammatory events by internal or external challenges can overload the balance with chronic secretion of TGF-B. Not only might this local excess lead to unresolved inflammation (9), but also, TGF-~/may reach the circulation. When elevated systemic levels of TGF-13 occur, either endogenously during disease states (4, 10), or after exogenous administration (11-14), a plethora of additional cellular targets and consequently, diverse signaling pathways with different outcomes, may become operative. Although the source(s) of the endogenous levels of blood TGF-/3 is uncertain in the autoimmune MRL/lpr mice, the spleen may contribute to the circulating pool in this and perhaps other models characterized by immune malfunction (4, 15). Why TGF-/~ accumulates is unknown, but TGF-/~ autoinduces its own synthesis (7). In addition, dysregulation of its activity because of persistence of the enzymatic machinery essential for its activation or insu~cient levels of inhibitors may be contributory. Nonetheless, whereas the tightly controlled, localized production of TGF-B occurs as a necessary component of an active inflammatory process, the aftermath of excess TGF-B, now found in the circulation, is to inhibit the same immune and inflammatory pathways. It is not inconceivable that this built-in negative feedback loop, occurring in TGF-B excess, evolved for the protection of the host during bouts of rampant inflammation. The dichotomy between local and systemically disseminated TGF-B was first documented in an experimental arthritis model in which local secretion or administration of TGF-13 was found to drive the inflammatory response, whereas systemic inoculation inhibited the same response (9, 13, 16) (Fig. 1). By what mechanism(s) does circulating TGF-3 promote immune suppression and can these pathways be used to clinical advantage? Recent evidence suggests that systemic TGF-13 targets endothelial ceUs, where it inhibits E-selectin expression to block adhesion and targeting of leukocytes to the site of inflammation (17) (Fig. 2). Moreover, since leukocytes are normally sensitive to a concentration gradient of chemotactic signals emanating from the site of inflammation (5, 9), the presence of elevated TGF-3 in the blood would destroy such an outward gradient (Fig. 2). Evidently, the effects of secreted or exogenous TGF-3 extend far beyond the control of cell growth and differentiation to include a myriad of other regulatory activities converging on phagocytic cells and activated lymphoid cells of all lineages (reviewed in 1, 2). While it
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide as a secretory product of mammalian cells
Nathan, C. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.12.1381691 · Cited by 4,350
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Self-citationTransforming growth factor-beta in disease: the dark side of tissue repair.
Border, W. A., & Ruoslahti, E. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115821 · Cited by 1,105
Accelerated Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-β
Mustoe, T. A., Pierce, G. F., Thomason, A., Gramates, P., Sporn, M. B., & Deuel, T. F. (1987) · Science · doi:10.1126/science.2442813 · Cited by 941
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M., Ding, A., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 861
Inhibition of Viral Replication by Interferon-γ-Induced Nitric Oxide Synthase
Karupiah, G., Xie, Q.-W., Buller, R. M. L., Nathan, C., Duarte, C., & MacMicking, J. D. (1993) · Science · doi:10.1126/science.7690156 · Cited by 816
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta.
Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q. W., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.605 · Cited by 655
Suppression of arthritis by an inhibitor of nitric oxide synthase.
McCartney-Francis, N., Allen, J. B., Mizel, D. E., Albina, J. E., Xie, Q. W., Nathan, C. F., & Wahl, S. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.749 · Cited by 645
Self-citationInduction of anergy or active suppression following oral tolerance is determined by antigen dosage.
Friedman, A., & Weiner, H. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6688 · Cited by 635
Maternal Rescue of Transforming Growth Factor-β 1 Null Mice
Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Roche, N. S., Sporn, M. B., & Roberts, A. B. (1994) · Science · doi:10.1126/science.8009224 · Cited by 495
Weinberg, J. B., Granger, D. L., Pisetsky, D. S., Seldin, M. F., Misukonis, M. A., Mason, S. N., Pippen, A. M., Ruiz, P., Wood, E. R., & Gilkeson, G. S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.651 · Cited by 435
Transforming Growth Factor-β in Leishmanial Infection: a Parasite Escape Mechanism
Barral-Netto, M., Barral, A., Brownell, C. E., Skeiky, Y. A. W., Ellingsworth, L. R., Twardzik, D. R., & Reed, S. G. (1992) · Science · doi:10.1126/science.1636092 · Cited by 434
Transforming growth factor beta (TGF-?) in inflammation: A cause and a cure
Wahl, S. M. (1992) · Journal of Clinical Immunology · doi:10.1007/bf00918135 · Cited by 407
Self-citationRacke, M. K., Dhib-Jalbut, S., Cannella, B., Albert, P. S., Raine, C. S., & McFarlin, D. E. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3012 · Cited by 378
Gazzinelli, R. T., Eltoum, I., Wynn, T. A., & Sher, A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3672 · Cited by 349
Silva, J. S., Twardzik, D. R., & Reed, S. G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.539 · Cited by 301
Transforming growth factor β: a matter of life and death
McCartney-Francis, N. L., & Wahl, S. M. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.3.401 · Cited by 299
Self-citationTransforming Growth Factor-β2 for the Treatment of Full-thickness Macular Holes
Glaser, B. M., Michels, R. G., Kuppermann, B. D., Sjaarda, R. N., & Pena, R. A. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31837-8 · Cited by 265
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.
Allen, J. B., Manthey, C. L., Hand, A. R., Ohura, K., Ellingsworth, L., & Wahl, S. M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.1.231 · Cited by 258
Self-citationBeck, L. S., DeGuzman, L., Lee, W. P., Xu, Y., Siegel, M. W., & Amento, E. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116904 · Cited by 233
Immune dysregulation in TGF- beta 1-deficient mice.
Christ, M., McCartney-Francis, N. L., Kulkarni, A. B., Ward, J. M., Mizel, D. E., Mackall, C. L., Gress, R. E., Hines, K. L., Tian, H., Karlsson, S., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.5.1936 · Cited by 229
Self-citationTransforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals.
Brandes, M. E., Allen, J. B., Ogawa, Y., & Wahl, S. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115073 · Cited by 220
Self-citationTransforming growth factor-beta inhibits E-selectin expression on human endothelial cells
Gamble, J. R., Khew-Goodall, Y., & Vadas, M. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.10.4494 · Cited by 210
Wahl, S. M., Allen, J. B., Weeks, B. S., Wong, H. L., & Klotman, P. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4577 · Cited by 206
Self-citationSantambrogio, L., Hochwald, G. M., Saxena, B., Leu, C. H., Martz, J. E., Carlino, J. A., Ruddle, N. H., Palladino, M. A., Gold, L. I., & Thorbecke, G. J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.1116 · Cited by 166
Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta.
Wahl, S. M., Allen, J. B., Costa, G. L., Wong, H. L., & Dasch, J. R. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.1.225 · Cited by 155
Self-citationAllen, J. B., Wong, H. L., Guyre, P. M., Simon, G. L., & Wahl, S. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115196 · Cited by 148
Self-citationHines, K. L., Kulkarni, A. B., McCarthy, J. B., Tian, H., Ward, J. M., Christ, M., McCartney-Francis, N. L., Furcht, L. T., Karlsson, S., & Wahl, S. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5187 · Cited by 91
Self-citationLowrance, J. H., O’Sullivan, F. X., Caver, T. E., Waegell, W., & Gresham, H. D. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1693 · Cited by 83
Cited by
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Metadata
- Authors
- Wahl, S. M.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-11-01
- Volume
- 180
- Issue
- 5
- Pages
- 1587-1590
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2085419002
- Cited by
- 486
- References
- 31
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.